Literature DB >> 22260837

The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study.

Wei-Qi Dai1, Yin-Qun Zhou, Ling Xu, Bin-Fang Wang, Xiao-Ming Fan, Jian-Ye Wu, Chun-Yan Wang, Xuan-Fu Xu, Chuan-Yong Guo.   

Abstract

BACKGROUND/AIMS: This study aimed to compare the 7d triple therapy with 3d and 5d triple therapies, to observe the effect of eradicating Helicobacter pylori (Hp) on treating duodenal ulcers.
METHODOLOGY: One hundred and sixteen patients who were confirmed duodenal ulcer active period and Hp positive were enrolled in the study. All the patients were divided into three groups: 3d group (n=39), 5d group (n=37) and 7d control group (n=40). All three groups were provided triple therapy first: rabeprazole, 10mg + furazolidone, 100mg + clarithromycin 250mg, twice a day for three days, five days and seven days, respectively. Then rabeprazole 10mg was provided once a day. Following the treatment, 13C urea breath test was performed to observe the Hp eradication rate. The symptoms of patients such as epigastralgia, burning pain and acidity were evaluated.
RESULTS: The Hp eradication rate was: 3d group 76% (28/37), 5d 89% (31/35) and 7d 91% (32/35). There was no significant difference between 5d and 7d group (p>0.05). But the rate of groups 5d and 7d was significantly higher than group 3d (p<0.05). All the three groups showed an improvement in symptoms such as epigastralgia, burning pain and acidity.
CONCLUSIONS: All three therapy schemes could alleviate symptoms of duodenal ulcer patients efficiently. But as far as eradicating Hp concerned, 5d and 7d therapies were better than 3d.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22260837     DOI: 10.5754/hge11241

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

Review 1.  Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication.

Authors:  Sang-Ho Park; Napapan Kangwan; Jong-Min Park; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

2.  Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study.

Authors:  Sreenivasulu Puram; Hyung Chae Suh; Seung Un Kim; Bharathi Bethapudi; Joshua Allan Joseph; Amit Agarwal; Venkateswarlu Kudiganti
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-27       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.